STOCK TITAN

Bank of America (NYSE: BAC) reports 4.0% beneficial stake in MacroGenics (MGNX)

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Bank of America Corporation filed an amended Schedule 13G reporting beneficial ownership of 2,556,475 shares of MacroGenics, Inc. common stock. This represents 4.0% of the class, based on 63,563,123 shares outstanding as of May 8, 2026, from MacroGenics’ May 13, 2026 Form 10-Q.

Bank of America reports no sole voting or dispositive power and shared voting and dispositive power over all 2,556,475 shares, held through wholly owned subsidiaries including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, and BofA Securities Europe SA. The filing confirms ownership of 5 percent or less of the class.

Positive

  • None.

Negative

  • None.
Beneficially owned shares 2,556,475 shares MacroGenics common stock beneficially owned by Bank of America
Percent of class 4.0% Portion of MacroGenics common stock class owned by Bank of America
Shares outstanding baseline 63,563,123 shares MacroGenics shares outstanding as of May 8, 2026 from May 13, 2026 Form 10-Q
Sole voting power 0 shares Shares over which Bank of America has sole voting power
Shared voting power 2,556,475 shares Shares over which Bank of America has shared voting power
Sole dispositive power 0 shares Shares over which Bank of America has sole dispositive power
Shared dispositive power 2,556,475 shares Shares over which Bank of America has shared dispositive power
beneficial ownership financial
"The beneficial ownership calculation relies on the 63,563,123 outstanding shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power financial
"Shared Voting Power 2,556,475.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 2,556,475.00"
Schedule 13G regulatory
"This statement on is being filed by Bank of America Corporation"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
parent holding company regulatory
"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What percentage of MacroGenics (MGNX) does Bank of America report owning in this Schedule 13G/A?

Bank of America reports beneficial ownership of 4.0% of MacroGenics common stock. This is based on 2,556,475 shares owned versus 63,563,123 shares outstanding as of May 8, 2026, cited from MacroGenics’ May 13, 2026 Form 10-Q.

How many MacroGenics (MGNX) shares does Bank of America beneficially own?

Bank of America reports beneficial ownership of 2,556,475 shares of MacroGenics common stock. These shares are held with shared voting and dispositive power through several wholly owned subsidiaries, including BofA Securities, Inc. and Bank of America N.A.

Does Bank of America have sole or shared voting power over its MacroGenics (MGNX) shares?

Bank of America reports 0 shares with sole voting power and 2,556,475 shares with shared voting power. It likewise reports 0 shares with sole dispositive power and 2,556,475 shares with shared dispositive power over MacroGenics common stock.

What share count did Bank of America use to calculate its 4.0% MacroGenics (MGNX) ownership?

The 4.0% beneficial ownership is calculated using 63,563,123 MacroGenics shares outstanding. This outstanding share figure comes from MacroGenics’ Form 10-Q filed May 13, 2026, which reports totals as of May 8, 2026.

Which Bank of America subsidiaries hold the MacroGenics (MGNX) position reported on this Schedule 13G/A?

The statement is filed by Bank of America on behalf of itself and wholly owned subsidiaries including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, and BofA Securities Europe SA, each classified under applicable Exchange Act provisions.

Does Bank of America report owning more than 5% of MacroGenics (MGNX)?

No. Bank of America explicitly reports ownership of 5 percent or less of MacroGenics’ common stock. The filing states a 4.0% beneficial ownership based on 2,556,475 shares versus 63,563,123 outstanding shares.





556099109

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The beneficial ownership calculation relies on the 63,563,123 outstanding shares disclosed in the Form 10-Q by the issuer on May 13, 2026, which reports share totals as of May 8, 2026.


SCHEDULE 13G



BANK OF AMERICA CORP /DE/
Signature:/s/ Monica Yako
Name/Title:Authorized Signatory
Date:08/03/2026